Abstract
After a 3-day washout, 141 depressed inpatients were enrolled in a 4-week controlled trial comparing conventional viloxazine 100mg 3 times daily and a new 300mg sustained release formulation. This was followed by an open phase during which 101 patients received the sustained release formulation for up to 6 months. No difference in withdrawals during the comparative phase occurred between the 2 groups. Reasons for withdrawal during the open long term treatment phase did not show any differences at any stage between patients originally assigned to the conventional or sustained release formulations. The results suggest that the sustained release formulation of viloxazine taken in a simplified regimen has clinical effects that are not significantly different to those obtained with the conventional formulation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
